Semaglutide with B12: Compounding Rules and Context

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This guide is part of the PlexusDx Education Hub, where we translate GLP-1 therapies, longevity peptides, and metabolic science into decisions you can actually use. Explore the full Peptides & GLP-1 library.

Searches for semaglutide paired with B12 usually start with a practical question: why is a vitamin mixed into a GLP-1 formulation, and is that combination legitimate? The answer runs through compounding law, a couple of years of drug-shortage history, and the specific reasons a pharmacy tailors a formula to one patient. Here is the full context.

What "compounded semaglutide" means

Compounded semaglutide is the active ingredient prepared by a state-licensed 503A compounding pharmacy under a valid prescription. It is a legally and factually distinct product from an FDA-approved brand medication. That distinction matters throughout this article, because compounded preparations follow a different oversight path than mass-manufactured drugs.

The three lanes a 503A pharmacy can work in

Federal law lets 503A pharmacies compound patient-specific prescriptions in three broad situations: when a product is not commercially available, when the drug sits on the FDA shortage list, and when an individual patient medically needs a formulation that differs in strength, combination, or vehicle. State pharmacy boards and the FDA share oversight of that activity.

How the shortage resolutions reshaped access

The FDA declared both semaglutide and tirzepatide in shortage in 2022, which opened the shortage lane for compounders. That situation changed when the agency resolved the semaglutide shortage in late 2024 and the tirzepatide shortage in early 2025. Those resolutions narrowed the window without closing it entirely: compounded versions can still be prepared under the patient-specific and not-commercially-available lanes where a clinician can justify it.

Why some formulations include B12

Cyanocobalamin, better known as vitamin B12, appears in a number of compounded GLP-1 formulas for a couple of reasons. For some patients it can ease injection-site irritation, and in people who are genuinely B12-deficient it may support energy and neurological health. It is a formulation choice a prescriber makes for a specific patient, not a standard ingredient added to every preparation.

Microdose formulas and patient-specific strengths

So-called microdose formulations deliver lower amounts than standard titration schedules, an approach sometimes used for patients who react strongly to label-directed doses. Any particular strength or combination is patient-specific and set by the prescriber's order. PlexusDx offers a Microdose GLP-1 Protocol within its Weight Management Protocols, alongside its Semaglutide Injection option.

Choosing safely and reading your biology first

Confirm the pharmacy is licensed in your state, that a prescriber performed a real clinical evaluation, and that labeling includes lot numbers, beyond-use dates, and storage guidance under the applicable USP standards. Be wary of any seller shipping without a prescription or marketing "research chemical" products. Underneath all of this sits your own metabolic terrain. Genes such as FTO, GLP1R, MC4R, and TCF7L2 shape baseline appetite and glucose handling, and the PlexusDx Precision Peptide Genetic Test reads 14 pathways, 49 peptides, 150+ genetic insights across them. It never predicts response to any formulation; it gives your provider upstream context before a GLP-1 protocol begins.

Questions worth bringing to a prescriber

Before any compounded GLP-1 formulation, a short checklist keeps the decision grounded. Confirm the pharmacy is licensed in your state and that a prescriber performed a genuine clinical evaluation rather than a rubber-stamp intake. Ask whether contraindications were reviewed against your history, and expect patient-specific labeling that includes lot numbers, beyond-use dates, and storage guidance under the applicable USP standards.

It is also worth asking why a particular formulation was chosen, including whether B12 is part of it and for what reason. Because a compounded product is not a generic and is not reviewed under the same FDA manufacturing process as a brand drug, its quality rests on the pharmacy's processes. A prescriber who can explain those choices, rather than defaulting to a one-size formula, is a good sign that the preparation was tailored to you.

Frequently Asked Questions

Is compounded semaglutide the same as the brand version?

No. Compounded semaglutide is not reviewed under the same FDA manufacturing process as a brand product and may differ in strength, vehicle, or added ingredients. It is not a generic in any regulatory sense, and quality varies by pharmacy. Verify state licensure and clinical oversight before use.

Why is B12 added to some semaglutide formulas?

Cyanocobalamin can reduce injection-site discomfort for some patients and may support those who are B12-deficient. It is a patient-specific choice made by the prescribing provider rather than a universal addition. Whether it belongs in your formulation is a clinical decision, not a marketing default.

Can compounded semaglutide still be made after the shortages ended?

Yes, in narrower circumstances. With the semaglutide shortage resolved in late 2024, compounding continues under the patient-specific and not-commercially-available lanes where clinically justified. The shortage lane specifically closed when the FDA declared the shortage over, so documentation of medical need matters more now.

Does genetics tell me which formulation to pick?

No. The Precision Peptide Genetic Test does not predict response to compounded semaglutide or any specific formula. It reads pathway variants such as FTO, and MC4R that describe baseline appetite and energy-balance biology, offering context that applies across every GLP-1 protocol you might discuss.

Keep reading across the PlexusDx Education Hub for more on peptides, metabolism, and the genetics beneath them. Return to the Education Hub.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.